MUC1 and breast cancer: Furthermore, high plasma autoantibody levels against two MUC1 glycoforms (core3MUC1 (GlcNAcβ1-3GalNAc-MUC1) and STnMUC1 (NeuAcα2,6GalNAc-MUC1)) have been described to reduce the incidence and increase the metastatic time in BC patients after a 15-year follow-up (64).